Boehringer Ingelheim News

A team of Boehringer Ingelheim scientists reports another milestone in the development of the BI-HEX® technology platform. A record productivity of more than 100 picogramms per cell per day was achieved in inoculum and fed-batch cultures of BI-HEX® Chinese hamster ovary (CHO) cell lines expressing a therapeutic monoclonal antibody.

Ingelheim, Munich/Germany, 29 October 2009 - Professor Steven V. Ley of the Cambridge University (UK) was awarded this year’s Heinrich Wieland Prize in appreciation of his extraordinary scientific achievements in the fields of synthesis, structural analysis and biological characterization of natural products.

Ingelheim/Germany and St. Joseph/MO, 26 October 2009 - Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica, Inc., announced today that it has closed its deal with Pfizer to acquire a significant portion of the Fort Dodge Animal Health business.

Ingelheim/Germany, 23 October 2009: Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of Micardis® (telmisartan) for the reduction of cardiovascular morbidity in patients with:

• Twynsta® delivers very powerful blood pressure (BP) reductions of up to 40/29 mmHg1 and a 24-hour BP response rate of up to 98%2 for hypertensive patients at risk of cardiovascular (CV) events
• Twynsta® combines the proven evidence base in CV outcomes of telmisartan and amlodipine3-9in a convenient single pill
• Twynsta® achieves superior BP reductions compared to
  

Micardis® is now indicated for cardiovascular (CV) risk reduction in patients with intolerance to angiotensin-converting enzyme (ACE) inhibitors.

• Boehringer Ingelheim3E8s Micardis® (telmisartan) is the ONLY treatment in its class approved by the U.S.

Ingelheim/Germany, 14 October 2009 – Boehringer Ingelheim today announced that the Mirapexin®/Sifrol® (pramipexole) new prolonged-release, once daily tablet has been granted marketing authorisation by the European Commission in all EU/EEA*) countries for the treatment of early and advanced idiopathic Parkinson’s disease (PD).

Boehringer Ingelheim has repeatedly and clearly stated that patents must not prevent access from life-saving drugs for HIV patients living in resource limited settings. In line with this and in order to accelerate access to anti-retroviral medicines, the company has initiated non-assert declarations in May 2007, well before the idea of the UNITAID patent pool was conceived.

Ingelheim/Germany, 28 September 2009 - Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials.

Ingelheim/Germany and St. Joseph/MO (22 September 2009) – Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S.